Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Validation of dried blood spot sampling for infliximab monitoring in adults with inflammatory bowel disease
NL-OMON43041Active, not recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Jan 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of infliximab in inflammatory bowel disease (IBD), sponsored by Amsterdam University Medical Center. Primary endpoint: Feasibility of dried blood spot sampling for infliximab and anti-infliximab antibody measurement. Started Jan 2017; status: active, not recruiting.
02
Drugs
infliximab
03
Conditions
inflammatory bowel disease (IBD)
Beyond the preview
Go deeper on NL-OMON43041.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON43041.